Clinical trials
Metastatic Breast Cancer ( HER2 Negative) clinical trials
Below are recruiting metastatic breast cancer ( her2 negative) clinical trials, each written for real people, not researchers. We’re tracking 493 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06107673RecruitingPhase 2
Pill vs chemo before breast cancer surgery
This study compares taking a daily pill (dalpiciclib with hormone therapy) versus standard chemotherapy before breast cancer surgery. It's for postmenopausal women with a common type of early breast cancer that is strongly hormone-receptor positive and HER2-negative.
Shijiazhuang, HebeiAges 18–75 - NCT06401421Recruiting
Blood test for tumor DNA after breast cancer chemo
This study tests a new blood test to see if it can find tiny bits of tumor DNA after chemotherapy. If you have a larger or higher-risk breast cancer and are getting chemotherapy before surgery, you may join. The test could help doctors know if your cancer is gone or if more treatment is needed.
Anchorage, AlaskaAges 18 years+ - NCT06598046RecruitingPhase 2
Utidelone and Capecitabine for triple-negative breast cancer brain metastases
This trial tests a combination of two chemotherapy drugs (Utidelone and Capecitabine) for people with triple-negative breast cancer that has spread to the brain. The goal is to see if the combination can shrink or control the brain tumors.
Zhengzhou, HenanAges 18 years+ - NCT07007169RecruitingPhase 2
Mediterranean diet study for early breast cancer
This trial tests whether eating a Mediterranean-style diet (rich in vegetables, fruits, whole grains, and healthy fats) can help improve outcomes for women with early breast cancer who are receiving chemotherapy. You will be asked to follow this diet and keep a food diary using an online tool.
EsbjergAges 18 years+ - NCT06254690RecruitingPhase 2
Pyrotinib dosing study for HER2-positive advanced breast cancer
This trial tests different doses of pyrotinib, a targeted therapy, for women with HER2-positive advanced breast cancer that has not yet been treated for recurrence. It aims to find the best dosing regimen to control the cancer.
Nanjing, JiangsuAges 18–70 - NCT06656624RecruitingPhase 2
Ribociclib plus hormone therapy for advanced breast cancer
This trial tests a new approach: starting with a targeted pill (ribociclib) plus hormone therapy (an aromatase inhibitor), instead of immediate chemotherapy, for women with a specific type of breast cancer (ER low-positive, HER2-negative) that is growing quickly. If eligible, you would not have received any prior treatment for your advanced cancer.
Nanjing, JiangsuAges 18–99 - NCT07145255RecruitingPhase 1/Phase 2
Study of MBRC-201 for advanced solid tumors
This trial tests a new drug, MBRC-201, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find the best dose and see if it helps shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT06821490Enrolling by invitation
TAD biopsy for HER2+ breast cancer with positive lymph nodes
This trial tests the accuracy of a targeted axillary dissection (TAD) after chemotherapy in people with HER2+ breast cancer that has spread to the lymph nodes. It aims to see if the TAD method can correctly identify which lymph nodes are cancer-free before surgery.
Valencia, ValenciaAges 18 years+ - NCT05000294RecruitingPhase 1/Phase 2
Atezolizumab plus tivozanib for hard-to-treat “cold” cancers
This early-stage study tests whether combining atezolizumab and tivozanib can shrink advanced, hard-to-treat cancers that do not strongly activate the immune system (“immunologically cold”). It is for people whose cancer has already been treated or has no good standard options.
Gainesville, FloridaAges 18–99 - NCT05983107RecruitingPhase 2
Chidamide/Everolimus for advanced breast cancer
This trial tests a combination of two drugs, chidamide and everolimus, for people with advanced HR+/HER2- breast cancer. It aims to see if the combination works for tumors with or without a PIK3CA gene mutation. You may be able to join if you've had previous treatment with CDK4/6 inhibitors and up to two prior chemotherapies.
Beijing, Beijing MunicipalityAges 18–75 - NCT05408845RecruitingPhase 2
Study drug vs standard care for HER2 salivary gland cancer
This Phase 2 trial tests how well ado-trastuzumab emtansine (and compares to two standard treatment options) works for salivary gland cancers that are HER2-positive or HER2-low. It aims to see whether the study drug can control cancer better and with acceptable side effects.
Birmingham, AlabamaAges 18 years+ - NCT07215364Recruiting
Exercise and quality of life in early breast cancer on hormone therapy
This trial tests if a supervised exercise program can improve quality of life for people with early-stage breast cancer who are currently taking hormone therapy (aromatase inhibitors with or without CDK4/6 inhibitors). It aims to see if exercise helps reduce side effects like fatigue and pain.
L'Hospitalet de Llobregat, BarcelonaAges 18 years+ - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Duarte, CaliforniaAges 18 years+ - NCT05372614RecruitingPhase 1
Testing trastuzumab deruxtecan and neratinib for HER2-positive cancers
This trial tests a combination of two targeted drugs, trastuzumab deruxtecan (Enhertu) and neratinib, for people with solid tumors that have a HER2 gene change. The goal is to see if the combination is safe and works well for cancers that have not responded to at least one prior treatment.
Duarte, CaliforniaAges 18 years+ - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Anchorage, AlaskaAges 18 years+ - NCT07046923RecruitingPhase 1
A study of LY4175408 for advanced cancer
This trial tests a new targeted drug (LY4175408) for people with certain advanced solid tumors (lung, endometrial, or triple negative breast cancer) who have already tried standard treatments. The goal is to see if the drug is safe and effective.
Stanford, CaliforniaAges 18 years+ - NCT04819243RecruitingPhase 2
Test a BRCA-targeted drug plan for advanced ER-positive breast cancer
This Phase 2 study tests how well a treatment plan using palbociclib followed by talazoparib (and possibly atezolizumab) works in certain people with advanced ER-positive breast cancer. It may help by targeting cancer biology linked to BRCA/HRD changes and by strengthening how the cancer is controlled.
Seoul, Gannam-guAges 19 years+ - NCT06706570Recruiting
PIK3CA gene testing for breast cancer
This trial tests for a specific gene change (PIK3CA mutation) in your breast cancer cells. The results will help doctors decide if a targeted treatment is right for you. It's for people with hormone-receptor-positive, HER2-negative breast cancer that has spread and not yet been treated in that setting.
Milan, MIAges 18 years+ - NCT04501523RecruitingPhase 2
ctDNA-guided immunotherapy boost after chemotherapy for triple-negative breast cancer
This Phase 2 study checks whether a blood test that looks for cancer DNA (ctDNA) can help decide who should get an extra 12-month immunotherapy treatment after standard chemotherapy and surgery. It may help reduce the chance of the cancer coming back in people with triple-negative breast cancer.
Guandong, GuangdongAges 18–80 - NCT05693766RecruitingPhase 2
Gene test guides treatment for hormone-positive breast cancer
This trial studies whether a gene-signature test can help guide treatment choices for people with hormone receptor–positive (ER and/or PR) breast cancer that has spread or can’t be fully removed. It may help find the best therapy approach after prior hormone therapy and targeted cancer medicine.
Birmingham, AlabamaAges 18 years+ - NCT05749588RecruitingPhase 2
Study for advanced triple-negative breast cancer after prior treatments
This Phase 2 trial tests a treatment for people with triple-negative breast cancer that has come back or spread and has continued to progress despite earlier therapies. It may help by trying a new approach in patients who still have enough health to safely receive more treatment.
ShanghaiAges 18 years+ - NCT06134375RecruitingPhase 1/Phase 2
TM plus capecitabine for triple-negative breast cancer
This trial tests a drug called tetrathiomolybdate (TM) combined with capecitabine for people with triple-negative breast cancer who still have cancer cells after standard chemotherapy and surgery. The goal is to see if this combination can help prevent the cancer from coming back.
Indianapolis, IndianaAges 18–80 - NCT06353997RecruitingPhase 2
New immunotherapy combination before surgery for triple-negative breast cancer
This trial tests a new combination of two immunotherapy drugs (INBRX-106 and pembrolizumab) given before surgery for people with early-stage triple-negative breast cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Los Angeles, CaliforniaAges 18 years+ - NCT06377852RecruitingPhase 3
Dosing study for older adults with advanced breast cancer
This trial studies how well different doses of CDK4/6 inhibitors (palbociclib or ribociclib) work in people aged 65 or older with HR+/HER2- metastatic breast cancer. It aims to find the best starting dose to balance effectiveness and side effects.
Chandler, ArizonaAges 65 years+
Hear when a new Metastatic Breast Cancer ( HER2 Negative) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic breast cancer ( her2 negative)?
- Yes. Clin2 currently lists 493 recruiting metastatic breast cancer ( her2 negative) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic breast cancer ( her2 negative) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic breast cancer ( her2 negative) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- HER2-negative Breast Cancer
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Metastatic Triple-negative Breast Cancer
- HER2-positive Metastatic Breast Cancer
- Metastatic HER2-Negative Breast Carcinoma
- HR-positive, HER2-negative Advanced Breast Cancer
- Hormone Receptor Positive / HER2-negative Breast Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.